Zelluna develops an off‑the‑shelf TCR‑guided natural killer (TCR‑NK) cell therapy platform aimed at treating solid tumors, which represent the majority of cancer cases. By combining engineered T‑cell receptor specificity with allogeneic NK cells, the company offers scalable, high‑affinity immunotherapies that can be manufactured in large batches and rapidly deployed for advanced solid‑cancer patients.
Funding
$4.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
TVFounders
Product
Problem
Current cell therapies have demonstrated curative outcomes primarily in liquid cancers, but solid tumors—representing the majority of cancer cases—remain largely untreatable due to limited tumor penetration, safety concerns, and manufacturing scalability challenges.
Solution
Zelluna is developing an off‑the‑shelf TCR‑guided natural killer (TCR‑NK) cell therapy platform designed specifically for solid cancers. The approach combines the high‑affinity tumor targeting of engineered T cell receptors with the potent, broad‑spectrum cytotoxicity of allogeneic NK cells. By using healthy donor NK cells, the product can be manufactured at large scale, reducing cost and improving global access. The TCR component directs NK cells to clinically validated antigens such as MAGE‑A4, PRAME, and KKLC‑1, enabling precise recognition of tumor cells while preserving a favorable safety profile. Early regulatory engagement and a pre‑IND pathway with the FDA position the lead program for rapid clinical entry, aiming to deliver safe and effective treatments for patients with advanced solid tumors.
Target Audience
Primary customers are pharmaceutical and biotech companies, as well as oncology clinical research groups, seeking advanced, scalable immunotherapies for patients with advanced solid tumors.
Features
- Off‑the‑shelf allogeneic NK cell backbone allowing large‑scale manufacturing and immediate availability
- Engineered T cell receptor (TCR) specificity targeting validated solid‑tumor antigens (e.g., MAGE‑A4, PRAME, KKLC‑1)
- Integrated platform architecture enabling rapid plug‑in of new TCR targets across the pipeline
- Proprietary IP covering the TCR‑NK construct and manufacturing process to protect the therapeutic class
- Designed for a favorable safety profile by leveraging NK cell innate regulation and precise TCR targeting
- Accelerated regulatory pathway with pre‑IND interactions supporting early‑phase clinical trials